Abstract Body

The treatment paradigm in Hepatitis B Virus (HBV) is on the cusp of major change, with a multitude of novel agents entering various phases of clinical trials. Novel therapies designed to cure HBV should ultimately restore antiviral immunity similar to that seen in those who naturally resolve HBV infection. Achieving HBsAg loss (or functional cure) in Chronic Hepatitis B (CHB) is dependent on a functional efficient HBV-specific adaptive immune response, with potential innate immune interaction; thus global immune restoration is likely to lead to improved treatment outcomes. The current direct antiviral therapies; although able to control viral replication and limit the progression to cirrhosis; require lifelong administration owing to a lack of sustained immune control off therapy, while immune modulation with interferon is only effective in a small proportion of patients. Better utilization of current therapies through combination and/or sequential strategies has recently been investigated by us (and others) and may merit further exploration. Major challenges in the employment of novel therapeutic approaches will be better definition of which cohorts of CHB patients should be targeted and the development of strategies that preferentially suppress HBV replication, reduce or degrade the cccDNA reservoir without generating excess liver damage. HBV therapy may be more effective and even less toxic in subjects with residual HBV-specific T cells without pre-existing liver inflammation. In keeping with this, I will discuss whether young patients with chronic hepatitis B (considered immune tolerant) with normal ALT levels, harbouring more HBV-specific T cells than their adult counterparts (categorised as immune active), may be better candidates for therapy than previously thought. I will discuss strategies to utilise current therapies to harness the immune response, discuss novel agents in the pipeline along with, in whom and how best to utilize these novel therapies in order to achieve functional cure with defined treatment endpoints in CHB. In addition, I will also consider risk-stratifying patients using non-invasive tests, to determine those patients at greatest risk for the development of hepatocellular carcinoma.